Literature DB >> 17052034

Cost-effectiveness of cognitive-behavioural therapy for mental disorders: implications for public health care funding policy in Canada.

Gail Myhr1, Krista Payne.   

Abstract

OBJECTIVE: Publicly funded cognitive-behavioural therapy (CBT) for mental disorders is scarce in Canada, despite proven efficacy and guidelines recommending its use. This paper reviews published data on the economic impact of CBT to inform recommendations for current Canadian mental health care funding policy.
METHOD: We searched the literature for economic analyses of CBT in the treatment of mental disorders.
RESULTS: We identified 22 health economic studies involving CBT for mood, anxiety, psychotic, and somatoform disorders. Across health care settings and patient populations, CBT alone or in combination with pharmacotherapy represented acceptable value for health dollars spent, with CBT costs offset by reduced health care use.
CONCLUSIONS: International evidence suggests CBT is cost-effective. Greater access to CBT would likely improve outcomes and result in cost savings. Future research is warranted to evaluate the economic impact of CBT in Canada.

Entities:  

Mesh:

Year:  2006        PMID: 17052034     DOI: 10.1177/070674370605101006

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  15 in total

Review 1.  Systematic review of intervention practices for depression in the workplace.

Authors:  Andrea D Furlan; William H Gnam; Nancy Carnide; Emma Irvin; Benjamin C Amick; Kelly DeRango; Robert McMaster; Kimberley Cullen; Tesha Slack; Sandra Brouwer; Ute Bültmann
Journal:  J Occup Rehabil       Date:  2012-09

2.  The need to teach cognitive-behavioural therapy.

Authors:  Gilbert Pinard
Journal:  Sultan Qaboos Univ Med J       Date:  2009-12-19

3.  Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.

Authors:  Krista A Payne; Gail Myhr
Journal:  Healthc Policy       Date:  2010-02

4.  We need psychologists!

Authors:  Meta van den Heuvel; Tony Barozzino; Karen Milligan; Elizabeth Ford-Jones; Sloane Freeman
Journal:  Paediatr Child Health       Date:  2016 Jan-Feb       Impact factor: 2.253

5.  Effect of Psychotherapy on Health Care Utilization in Children With Inflammatory Bowel Disease and Depression.

Authors:  Divya Keerthy; Ada Youk; Arvind I Srinath; Nasuh Malas; Simona Bujoreanu; Athos Bousvaros; David Keljo; David R DeMaso; Eva M Szigethy
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

6.  U-CARE: Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer--a clinical trial protocol.

Authors:  Susanne Mattsson; Sven Alfonsson; Maria Carlsson; Peter Nygren; Erik Olsson; Birgitta Johansson
Journal:  BMC Cancer       Date:  2013-09-11       Impact factor: 4.430

7.  Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis.

Authors:  Shefali Kumar; Megan Jones Bell; Jessie L Juusola
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

8.  Understanding clinician attitudes towards implementation of guided self-help cognitive behaviour therapy for those who hear distressing voices: using factor analysis to test normalisation process theory.

Authors:  Cassie M Hazell; Clara Strauss; Mark Hayward; Kate Cavanagh
Journal:  BMC Health Serv Res       Date:  2017-07-24       Impact factor: 2.655

9.  Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial.

Authors:  Filip Smit; Godelief Willemse; Peter Meulenbeek; Marc Koopmanschap; Anton van Balkom; Philip Spinhoven; Pim Cuijpers
Journal:  Cost Eff Resour Alloc       Date:  2009-04-24

10.  Barriers to disseminating brief CBT for voices from a lived experience and clinician perspective.

Authors:  Cassie M Hazell; Clara Strauss; Kate Cavanagh; Mark Hayward
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.